Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a Latin American referral population

Digestion

Volumn 88, Issue 4, 2013, Pages 222-228

  Juliao, Fabian ^a,c   Marquez, Juan ^b   Aristizabal, Natalia ^a   Yepes, Carlos ^a,c   Zuleta, Julio ^a   Gisbert, Javier P ^d  

^a HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^b Clinica Las Americas   (Colombia)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Anti tumor necrosis factor ; Infliximab; Tumor necrosis factor ; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; COLON RESECTION; CONTINUOUS INFUSION; DESCRIPTIVE RESEARCH; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; ELECTIVE SURGERY; FEMALE; FOLLOW UP; HEALING; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MALE; OUTCOME ASSESSMENT; PATIENT REFERRAL; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; ADOLESCENT; AGED; CHILD; COLOMBIA; LONG TERM CARE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; COLOMBIA; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING; YOUNG ADULT;

EID: 84892180090     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000355529     Document Type: Article

References (20)

1. Juliao F, Florez JF, Ruiz MH, et al: Phenotypes and natural history of inflammatory bowel disease (IBD) in a referral population in Medellin, Colombia. Rev Col Gastroenterol 2010; 25: 240-251.
2. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al: The natural history of corticosteroid therapy for inflammatory bowel disease: a population based study. Gastroenterology 2001; 121: 255-260.
3. Langholz E, Munkholm P, Davidsen M, Binder V: Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103: 1444-1451.
4. Penna C, Dozois R, Tremaine W, et al: Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38: 234-239.
5. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT: Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34: 1705-1709.
6. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT: Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
7. Rutgeerts P, Sandborn WJ, Feagan BG, et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.
8. Sandborn WJ, Rutgeerts P, Feagan BG, et al: Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-1260.
9. Gisbert JP, Gonzalez-Lama Y, Mate J: Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 25: 19-37.
10. Stange EF, Travis SPL, Vermeire S, et al: European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2008; 2: 1-23.
11. Satsangi J, Silverberg MS, Vermeire S, et al: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753.
12. Papa A, Mocci G, Bonizzi M, et al: Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol 2009; 104: 1575-1586.
13. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987; 317: 1625-1629.
14. Panaccione R, Rutgeerts P, Sandborn WJ, et al: Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 674-688.
15. Ferrante M, Vermeire S, Fidder H, et al: Longterm outcome after infliximab for refractory ulcerative colitis. J Crohn's Colitis 2008; 2: 219-225.
16. Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-San Roman A, et al: Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008; 55: 1609-1614.
17. Barreiro M, Lorenzo A, Dominguez-Munoz E, et al: W1121 clinical efficacy and mucosal healing rate of infliximab in steroid-dependent ulcerative colitis: a prospective long-term followup study. Gastroenterology 2009; 136:A-658.
18. Panaccione R, Ghosh S, Middleton S, et al: Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J Crohn's Colitis 2011;5:13.
19. Oussalah A, Evesque L, Laharie D, et al: A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010; 105: 2617-2625.
20. Oussalah A, Danese S, Peyrin-Biroulet L: Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets 2009; 11: 156-175.